---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-116795"
form_type: "8-K"
ticker: "SGMT"
cik: "0001400118"
company_name: "Sagimet Biosciences Inc."
filed_at: "2023-11-13T23:59:59+00:00"
generated_at: "2026-06-08T04:46:32.421530+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Sagimet reports Q3 net loss of $6.4M; cash $101.8M; NASH data due Q1 2024

## Summary
- Net loss $6.4M vs $7.5M in Q3 2022; revenue $2.0M from milestone vs zero year-ago.
- Cash $101.8M, expected to fund operations at least 12 months.
- Phase 2b FASCINATE-2 (denifanstat) week 52 liver biopsy results expected Q1 2024.
- Two AASLD abstracts accepted; preclinical FASN inhibitor + semaglutide combo data shown.
- Ascletis enrolled 120 patients in Phase 3 denifanstat + bevacizumab for recurrent GBM.

## SEC filing metadata
- accession: 0001104659-23-116795
- form_type: 8-K
- ticker: SGMT
- cik: 0001400118
- company_name: Sagimet Biosciences Inc.
- filed_at: 2023-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1400118/000110465923116795/0001104659-23-116795-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1400118/000110465923116795/tm2330502d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-116795
- JSON: https://secwatch.observer/filing/0001104659-23-116795.json
- Plain text: https://secwatch.observer/filing/0001104659-23-116795.txt

## Key facts
- Earnings Releases
  Sagimet Biosciences Inc. reported the third quarter ended September 30, 2023 results: revenue Revenues for the third quarter ended September 30, 2023 were $2.0 million, net income Net loss for the third quarter ended September 30, 2023 was $6.4 million.
  - Period: the third quarter ended September 30, 2023
  - Revenue: Revenues for the third quarter ended September 30, 2023 were $2.0 million
  - Net income: Net loss for the third quarter ended September 30, 2023 was $6.4 million
  - Result: reported results
  source text: On November 13, 2023, Sagimet Biosciences Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1400118/000110465923116795/0001104659-23-116795-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.